Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Ligand Pharmaceuticals (LGND) over the last 4 years, with Q4 2013 value amounting to $42.3 million.

  • Ligand Pharmaceuticals' Treasury Shares changed 0.0% to $42.3 million in Q4 2013 from the same period last year, while for Dec 2013 it was $42.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $42.3 million for FY2013, which is 0.0% changed from last year.
  • Ligand Pharmaceuticals' Treasury Shares amounted to $459213.0 in Q3 2025, which was down 812.62% from $462834.0 recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Treasury Shares registered a high of $512361.0 during Q2 2024, and its lowest value of $162152.0 during Q1 2022.
  • For the 5-year period, Ligand Pharmaceuticals' Treasury Shares averaged around $372358.7, with its median value being $372513.0 (2023).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Treasury Shares grew by 13.03% in 2011, and later changed by 0.0% in 2012.
  • Quarter analysis of 4 years shows Ligand Pharmaceuticals' Treasury Shares stood at $42.2 million in 2010, then grew by 0.13% to $42.3 million in 2011, then changed by 0.0% to $42.3 million in 2012, then changed by 0.0% to $42.3 million in 2013.
  • Its last three reported values are $42.3 million in Q4 2013, $42.3 million for Q3 2013, and $42.3 million during Q2 2013.